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Pharmacodynamic Tumor Model
Summary
A tumor model was developed that:
• Describes the effects of radiation and radiosensitizer treatment
on tumor volume
• Captures long-term tumor dynamics including tumor eradication
and tumor regrowth with different rates
• Can be used to predict tumor eradication (Tumor Static Exposure)
Introduction
We introduce a pharmacodynamic model that describes the tumor volume evolution during and after treatment with radiation and radiosensitizing agents. A key
contribution is the inclusion of a long-term radiation effect, which allows the model to describe distinct tumor behaviors including tumor eradication and tumor
regrowth with different growth rates. The model also accounts for the effects of combining radiation therapy with radiosensitizing treatment. The was model fitted
to data from xenograft experiments using a clinically-relevant administration schedule.
Tumor volume data were generated in FaDu xenograft mouse models.
Animals were divided into the following four groups with N = 9 animals per
group: vehicle, radiation (2 Gy), and radiation (2 Gy) and radiosensitizer
(25 mg/kg or 100 mg/kg). Animals received treatment five days a week
for six weeks.
A pharmacodynamic tumor model was adapted from one of our
previously-published models [1,2]. A short-term radiation effect is
described by allowing lethally irradiated cells up to one more cell
division before apoptosis. Long-term radiation effects are described by
an irreversible inhibition of the tumor growth rate. The radiosensitizing
agent was assumed to stimulate both processes.
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The model is given by the following system of differential equations
where 𝑘𝑔 is the growth rate, 𝑘𝑘 the kill rate, 𝛼 and 𝛽 the parameters
associated with short- and long-term radiation effects, respectively, and a
and b are pharmacodynamics parameters associated with the
radiosensitizer. The function 𝐹 describes the fraction of irradiated cells
that are transferred from 𝑉1 to 𝑈1 during each instance of irradiation. 𝐹 is
given by
 𝐹 𝐷, 𝐶 = 1 − exp − 1 + 𝑏 𝐶  𝛽𝐷  
 
 
 
 
Individual Fit
The tumor model was fitted to the data using a mixed-effects approach[3].
Between-subect variability was accounted for in initial tumor volume, and both the
short- and long-term radiation effects. Examples of individual fits for each
treatment arm are shown below.
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The calibrated tumor model can be used to predict which radiation doses and
radiosensitizer exposures that lead to tumor eradication [1,2]. This occurs when the
long-term radiation effect inhibits 𝑘𝑔 to a value below 𝑘𝑘. The net growth rate
𝑘𝑔 − 𝑘𝑘 will then be negative and the tumor will shrink. The combinations of total
radiation doses and concurrent plasma concentrations of the radiosenstizer that
will lead to tumor regression is shown in the figure below (green area).
The estimated tumor doubling time was 5 days. The model predicts that each
fraction of 2 Gy kills 15 % of the proliferating cells. If radiation is preceeded by
radiosensitizing treatment (100 mg/kg) 25 % of the proliferating cells are killed.
When radiation therapy is given
alone, a total dose of 120 Gy
predicted to lead to tumor
eradication in a typical individual.
When radiation therapy is
preceeded by radiosensitizing
treatment (100 mg/kg), the total
radiation dose needed for tumor
eradication is decreased to 30 Gy.
